九强生物(300406) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥393,894,885.38, representing a 5.49% increase compared to ¥373,395,954.06 in the same period last year[4] - Net profit attributable to shareholders was ¥120,648,449.77, an increase of 8.67% from ¥111,021,507.44 year-on-year[4] - Basic and diluted earnings per share were both ¥0.21, reflecting a 10.53% increase from ¥0.19 in the same period last year[4] - Net profit for the quarter was ¥120,219,484.04, representing a 9.2% increase from ¥109,943,665.23 in the same period last year[70] - Earnings per share (EPS) for the quarter was ¥0.21, compared to ¥0.19 in the previous year, indicating a growth of 10.5%[70] Cash Flow and Liquidity - The net cash flow from operating activities increased by 28.08%, reaching ¥17,550,800.52 compared to ¥13,703,432.30 in the previous year[4] - The company reported a significant increase in cash inflow from operating activities, totaling ¥413,326,787.63, compared to ¥364,421,827.85 in the previous year[19] - The company reported a significant increase in cash and cash equivalents, with a balance of ¥1,033,781,508.49 at the end of the reporting period, compared to ¥724,037,812.52 at the beginning[14] - The net cash flow from financing activities was CNY 17,131,284.67, compared to a negative cash flow of CNY -753,935.03 in the previous period, indicating a significant improvement[24] - The company's cash and cash equivalents increased by CNY 309,743,695.97, contrasting with a decrease of CNY -18,757,060.63 in the prior year[24] - The total cash and cash equivalents at the end of the period reached CNY 1,021,374,176.44, up from CNY 321,963,005.37 at the end of the previous period[24] Assets and Equity - Total assets at the end of the reporting period were ¥5,278,102,107.76, up 1.98% from ¥5,175,748,806.32 at the end of the previous year[4] - Shareholders' equity attributable to the parent company increased by 3.31% to ¥3,847,752,663.85 from ¥3,724,591,909.76[4] - The total assets of the company stood at ¥5,278,102,107.76, a slight increase from ¥5,175,748,806.32[63] - The company's total equity increased to ¥3,842,297,658.70, up from ¥3,721,550,156.64, reflecting a growth of 3.2%[63] - Total liabilities decreased to ¥1,435,804,449.06 from ¥1,454,198,649.68, showing a reduction of 1.3%[63] Investments and Acquisitions - The company achieved a net cash flow from investment activities of ¥275,345,935.07, a turnaround from a negative cash flow of -¥31,458,731.76 in the same period last year[19] - The company’s subsidiary, Fuzhou Maixin Biotechnology Development Co., Ltd., acquired a 25.21% stake in Xiamen Longjin Biotechnology Co., Ltd. for CNY 32 million[38] Shareholder Information - The total number of common shareholders at the end of the reporting period was 13,186[53] - The largest shareholder, China Pharmaceutical Investment Co., Ltd., holds 16.63% of shares, totaling 97,854,687 shares[53] - Liu Xi, a natural person, holds 11.39% of shares, totaling 67,013,676 shares[53] - The company has a total of 29,601,709 restricted shares at the end of the period, with 376,005 shares released during the current period[56] - The company completed a share repurchase plan, affecting the number of restricted shares held by executives[56] - The company plans to unlock 25% of the restricted shares held by executives on the first trading day of the year[56] - The report indicates that there were no new shares issued during the current period[56] Expenses and Income - Management expenses increased by 33.39% year-on-year, primarily due to increased depreciation from capitalized construction projects and amortization from the fifth phase of equity incentives[51] - Interest income surged by 187.89% year-on-year, attributed to increased deposit interest income[51] - The company recorded a 50.39% decrease in investment income, down to CNY 1,115,166.92 from CNY 2,247,656.12 in the previous year[51] - The company reported a loss of CNY 290,627.64 from asset disposals, a significant decline of 166.14% compared to the previous period[51] Research and Development - Research and development expenses increased to ¥42,889,988.58, up from ¥36,221,121.73, marking a rise of 18.5%[65] Future Outlook - The company is expected to achieve rapid development in the next five years through strategic collaboration with Mai Xin Bio, enhancing its channel advantages and brand effect[12] - The company has not disclosed any new product launches or significant market expansion strategies in the current report[66] - The company has not reported any new investment activities in the current quarter[59]